Title of article :
High Yield Overexpression, Refolding, Purification and Characterization of Pseudomonas aeruginosa Type B-Flagellin: An Improved Method Without Sonication
Author/Authors :
Faezi, Sobhan Departments of Mycobacteriology and Pulmonary Research - Pasteur Institute of Iran , Bahrmand, Ahmad Reza Departments of Mycobacteriology and Pulmonary Research - Pasteur Institute of Iran , Mahdavi, Mehdi Departments of Immunology - Pasteur Institute of Iran , Davar Siadat, Mehdi Departments of Mycobacteriology and Pulmonary Research - Pasteur Institute of Iran , Nikokar, Iraj Laboratory of Microbiology and Immunology of Infectious Diseases - Guilan University of Medical Sciences , Sardari, Soroush Biotechnology Research Center - Drug Design and Bioinformatics Group - Pasteur Institute of Iran , Alan Holder, Ian Departments of Microbiology and Surgery - University of Cincinnati - and Shriners Burns Institute - USA
Abstract :
Pseudomonas aeruginosa as an opportunistic pathogen is a significant cause of acute and chronic infections in patients with compromised defenses. This bacterium is motile via a single polar flagellum made of polymerized flagellin subunits differentiated into two major serotypes: A and B. flagellin plays an important role as a virulence factor in the adhesion, colonization and invasion of P. aeruginosa into host epithelial cells. To develop a functional vaccine that can be used in practical application to prevent and treat infection, type B-flagellin was produced as recombinant protein. In this work, the fliC gene was introduced into a pET28a vector and expressed in Escherichia coli BL21 (DE3). The expressed recombinant protein was purified by a modified method without sonication using a HisTrap affinity column. The functional activities of produced flagellin were confirmed by ELISA, western blot analysis, motility inhibition assay and opsonophagocytosis test. The purification process of the type B-flagellin was lead to a high yield. The produced recombinant type B-flagellin showed high biological activity in all of these standard assays. In conclusions, this report provides the new protocol to efficiently obtain the type B-flagellin with high biological activity and immunogenicity. This immunogen can be introduced as an adjuvant or vaccine in the future study.
Keywords :
Pseudomonas aeruginosa , flagellin protein , pET28a , purification , vaccine
Journal title :
International Journal of Molecular and Cellular Medicine(IJMCM)